Research Use Only Notice: This article is about GHRP-2 as a laboratory research material. It only covers in-vitro experiments and published laboratory-animal studies.
It is not a guide for human or veterinary use, dosing, injection, diagnosis, or treatment. Researchers should follow the lot-specific certificate of analysis (COA), their study protocol, and their institution’s safety rules.
GHRP-2, also called pralmorelin or KP-102, is a synthetic peptide made of six amino-acid residues. It is studied as an agonist of the growth hormone secretagogue receptor type 1a, usually shortened to GHS-R1a.[1][2]

Published GHRP-2 research includes receptor-signaling studies, pituitary-cell assays, laboratory-animal experiments, and human diagnostic studies. This article focuses only on in-vitro and laboratory-animal research.
Results can change with the species, cell type, dose, and test method, so findings from one study should not be treated as a general rule.
Basic Identity
| Item | GHRP-2 Free Peptide (parent record) |
|---|---|
| Other names | Pralmorelin, KP-102 |
| Sequence | D-Ala1-D-2-Nal2-Ala3-Trp4-D-Phe5-Lys6-NH2 |
| Length | 6 residues |
| Molecular formula | C45H55N9O6 |
| Average molecular weight | About 818.0 g/mol for the free peptide |
| Monoisotopic mass | 817.4275 Da[1] |
| CAS Registry Number (parent/free peptide) | 158861-67-7; see the lot-specific COA for the counterion and molecular-weight basis of the supplied form |
| PubChem CID | 6918245 |
The sequence and residue numbering above refer to the free peptide backbone as recorded in PubChem.[1]
The molecular weight above is for the free peptide. A research lot may contain a counterion such as acetate, hydrochloride, or trifluoroacetate, as well as water or residual solvent.
For concentration calculations, use the form and net peptide content stated on the lot-specific COA rather than relying only on the free-peptide molecular weight.
How GHRP-2 Works in Research Models
GHS-R1a is a G-protein-coupled receptor found in pituitary and hypothalamic tissue. It is the canonical receptor through which GHRP-2 is studied for growth-hormone secretagogue activity.[3]
Studies using ghrelin and other GHS-R1a agonists in pituitary-cell systems have linked receptor activation to phospholipase C/protein kinase C, adenylate cyclase/protein kinase A, and calcium-dependent signaling pathways. The relative contribution of each pathway may differ among ligands and experimental systems.[4]
For GHRP-2 itself, Doi et al. (2004) reported that KP-102 directly stimulated GH secretion from cultured rat anterior pituitary cells, although its in-vitro GH-releasing potency was significantly weaker than that of GHRH.
In hypophysectomized rats, the GH-releasing activity of KP-102 was completely absent, while in median eminence-lesioned rats (in which hypothalamic-pituitary connections are disrupted) it was still present but the secreted GH amounts were significantly less than those in normal rats.
This indicates that GHRP-2 can act directly on pituitary cells, while an intact median eminence and endogenous GHRH are needed for the full in-vivo response. The same study also found that the GH-releasing activity of KP-102 was less sensitive to inhibition by endogenous somatostatin than that of exogenous GHRH.
Furthermore, in awake rats KP-102 showed stronger GH-releasing activity than exogenous GHRH, whereas in pentobarbital-anesthetized rats the two were nearly equipotent, and in awake dogs KP-102 stimulated GH release while GHRH failed to elevate serum GH levels.[2][5]
What the Swine Comparison Showed
A conscious-swine study compared GHRP-2, GHRP-6, and ipamorelin under the same test conditions. The values below apply only to that study.[6]
| Compound | ED50 | Emax |
|---|---|---|
| GHRP-2 | 0.6 nmol/kg | 56 ± 6 ng GH/mL plasma |
| Ipamorelin | 2.3 ± 0.03 nmol/kg | 65 ± 0.2 ng GH/mL plasma |
| GHRP-6 | 3.9 ± 1.4 nmol/kg | 74 ± 7 ng GH/mL plasma |
In this experiment, GHRP-2 had the lowest ED50, which means a smaller molar amount was needed to reach half of its maximum response. It also had the lowest Emax, so it did not produce the highest maximum growth hormone level in the same study.
As a reference, in-vitro potency for GHRP-6 in rat primary pituitary cells from the same study was EC50 = 2.2 ± 0.3 nmol/L (Emax = 100%).[6]
These results do not prove that GHRP-2 has the highest receptor affinity, and they should not be applied to every species or assay.
Other Findings in Laboratory Animals
In the same swine study, GHRP-2 and GHRP-6 increased ACTH and cortisol. ACTH and cortisol responses after ipamorelin were not significantly different from those observed after GHRH stimulation, even at doses more than 200-fold higher than its GH ED50.
None of the tested secretagogues caused a significant change in FSH, LH, prolactin, or TSH under those test conditions.[6]
Hirotani et al. (2005) investigated the mechanism of KP-102-induced ACTH release in conscious rats under conditions that minimized stress influence.
Intravenous KP-102 increased plasma ACTH significantly but did not stimulate ACTH release from rat primary pituitary cells.
A CRF antagonist markedly inhibited KP-102-induced ACTH release, whereas an AVP antagonist or anti-AVP antiserum did not. These findings suggest that KP-102 acts via the hypothalamus to stimulate ACTH release, mediated mainly by the release of corticotropin-releasing factor (CRF).[7]
Food-intake results are also not the same in every model.
Liu et al. (2004) found that in fed S5B rats, GHRP-2 dose-dependently increased intake of a low-fat diet but not a high-fat diet, whereas in the fasted state neither strain showed the same increase for either diet.
These findings suggest that feeding status, strain, and diet composition should be controlled or recorded when food intake could confound the primary endpoint.[8]
Common Laboratory Research Uses
- Receptor studies: measuring GHS-R1a activation, calcium signaling, or other cell responses.
- Pituitary-cell studies: testing direct growth hormone release in cultured pituitary cells.
- Laboratory animal studies: comparing growth hormone, ACTH, cortisol, feeding, or hypothalamic-pituitary responses under an approved protocol.
Comparisons between GHRP-2 and other compounds should use the same species or cell system, the same units, the same sampling times, and the same analytical method. Data from unrelated studies should not be combined into a simple ranking.
Laboratory Handling and Storage
Laboratory Handling Notice: The following points are for professional laboratory sample preparation only. They are not human or veterinary reconstitution, dosing, injection, or administration instructions.
- Check the COA first. Confirm the salt form, molecular-weight basis, purity result, and net peptide content before making concentration calculations.
- Follow lot-specific storage instructions. When supported by the supplier’s stability data, −20°C is commonly used for long-term storage of lyophilized research peptides. Protect the vial from moisture and unnecessary temperature cycling.
- Choose the solvent for the assay. Solubility can change with salt form, pH, concentration, and buffer. Test a small amount before preparing a full stock solution.
- Limit solution storage. Make small laboratory aliquots when practical, protect them from light, and avoid repeated freeze-thaw cycles. Do not claim a fixed solution shelf life unless it has been tested for that solvent and concentration.
- Check recovery after filtration. If membrane filtration is used during cell-culture sample preparation, select a low-binding membrane and verify peptide recovery. Do not describe the final material as sterile unless the filtration and aseptic process have been appropriately validated.
How to Read the COA
HPLC purity, identity, and peptide content are different measurements. An HPLC area percentage shows the relative size of detected chromatographic peaks under one method.
It does not automatically equal the amount of peptide in the vial. Mass spectrometry can support identity by checking molecular mass, while water, counterion content, and residual solvents need separate tests when they are part of the specification.[9][10]
The analytical method should be suitable for its purpose. For example, an identity test, a purity test, and a content assay do not have the same job and may need different validation checks.
LC-MS and LC-MS/MS can also help find or identify peptide-related impurities that may be hard to judge from a single HPLC trace. Although ICH and FDA documents are written primarily for regulated drug development, their analytical principles—such as distinguishing identity, purity, assay, and impurity profiling—can provide useful quality-control context for research peptides.[9][10]
A COA showing results within the supplier’s stated specifications only confirms the reported tests for that lot. It does not by itself prove sterility, human safety, clinical effectiveness, or suitability for veterinary use.
Authoritative External Sources
- PubChem. Pralmorelin, CID 6918245. https://pubchem.ncbi.nlm.nih.gov/compound/Pralmorelin
- Doi N, Hirotani C, Ukai K, Shimada O, Okuno T, Kurasaki S, Kiyofuji T, Ikegami R, Futamata M, Nakagawa T, Ase K, Chihara K. Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):857-867. doi:10.1055/s-0031-1297041. https://pubmed.ncbi.nlm.nih.gov/15646370/
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. https://pubmed.ncbi.nlm.nih.gov/8688086/
- Malagón MM, Luque RM, Ruiz-Guerrero E, Rodríguez-Pacheco F, García-Navarro S, Casanueva FF, Gracia-Navarro F, Castaño JP. Intracellular signaling mechanisms mediating ghrelin-stimulated growth hormone release in somatotropes. Endocrinology. 2003;144(12):5372-5380. doi:10.1210/en.2003-0723. https://pubmed.ncbi.nlm.nih.gov/12960033/
- Nakagawa T, Ukai K, Ohyama T, et al. Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats. Life Sciences. 1996;59(9):705-712. https://pubmed.ncbi.nlm.nih.gov/8761023/
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. https://pubmed.ncbi.nlm.nih.gov/9849822/
- Hirotani C, Oki Y, Ukai K, Okuno T, Kurasaki S, Ohyama T, Doi N, Sasaki K, Ase K. ACTH releasing activity of KP-102 (GHRP-2) in rats is mediated mainly by release of CRF. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2005;371(1):54-60. doi:10.1007/s00210-004-1009-3. https://pubmed.ncbi.nlm.nih.gov/15645295/
- Liu X, York DA, Bray GA. Regulation of ghrelin gene expression in stomach and feeding response to a ghrelin analogue in two strains of rats. Peptides. 2004;25(12):2171-2177. https://pubmed.ncbi.nlm.nih.gov/15572207/
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf
- U.S. Food and Drug Administration. Complex Mixtures and Peptides. https://www.fda.gov/industry/generic-drug-user-fee-amendments/fys-2013-2017-regulatory-science-report-complex-mixtures-and-peptides
Research Use Only Disclaimer
Research Use Only: The GHRP-2 material supplied by SaiyanMed is sold solely as a laboratory research reagent and is not approved by the relevant regulatory authorities as a human or veterinary drug product. This statement refers to the SaiyanMed research product and should not be interpreted as a description of the regulatory status of all pralmorelin-containing medicinal products worldwide.
This article provides general scientific information regarding standard laboratory research contexts only, and does not constitute a validated experimental protocol, medical guidance, clinical guidance, veterinary guidance, or treatment advice.